Treatment of cachexia: An overview of recent developments

Stephan Von Haehling; Stefan D. Anker

doi:10.1016/j.ijcard.2014.10.026

Treatment of cachexia: An overview of recent developments

Stephan Von Haehling, Stefan D. Anker

Istituto San Raffaele Pisana

Research output: Contribution to journal › Article › peer-review

Abstract

Bodywasting in the context of chronic illness is associatedwith reduced quality of life and impaired survival. Recent clinical trials have investigated different approaches to improve patients' skeletalmusclemass and strength, exercise capacity, and survival in the context of cachexia and bodywasting,many of themin patientswith cancer. The aim of this article is to summarise clinical trials published over the last two years. Therapeutic approaches discussed here include appetite stimulants like megestrol acetate, L-carnitine, or melatonin, anti-inflammatory drugs like thalidomide, pentoxyphylline, or a monoclonal antibody against interleukin-1α as well as ghrelin and the ghrelin agonist anamorelin, nutritional support, and anabolics like enobosarm and testosterone.

Original language	English
Pages (from-to)	726-742
Number of pages	17
Journal	International Journal of Cardiology
Volume	184
Issue number	1
DOIs	https://doi.org/10.1016/j.ijcard.2014.10.026
Publication status	Published - 2015

Keywords

Cachexia
Cancer
Therapy
Wasting

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine
Medicine(all)

Access to Document

10.1016/j.ijcard.2014.10.026

Cite this

@article{d92def021c224bfaa8ca4877903aef70,

title = "Treatment of cachexia: An overview of recent developments",

abstract = "Bodywasting in the context of chronic illness is associatedwith reduced quality of life and impaired survival. Recent clinical trials have investigated different approaches to improve patients' skeletalmusclemass and strength, exercise capacity, and survival in the context of cachexia and bodywasting,many of themin patientswith cancer. The aim of this article is to summarise clinical trials published over the last two years. Therapeutic approaches discussed here include appetite stimulants like megestrol acetate, L-carnitine, or melatonin, anti-inflammatory drugs like thalidomide, pentoxyphylline, or a monoclonal antibody against interleukin-1α as well as ghrelin and the ghrelin agonist anamorelin, nutritional support, and anabolics like enobosarm and testosterone.",

keywords = "Cachexia, Cancer, Therapy, Wasting",

author = "{Von Haehling}, Stephan and Anker, {Stefan D.}",

year = "2015",

doi = "10.1016/j.ijcard.2014.10.026",

language = "English",

volume = "184",

pages = "726--742",

journal = "International Journal of Cardiology",

issn = "0167-5273",

publisher = "Elsevier Ireland Ltd",

number = "1",

}

TY - JOUR

T1 - Treatment of cachexia

T2 - An overview of recent developments

AU - Von Haehling, Stephan

AU - Anker, Stefan D.

PY - 2015

Y1 - 2015

N2 - Bodywasting in the context of chronic illness is associatedwith reduced quality of life and impaired survival. Recent clinical trials have investigated different approaches to improve patients' skeletalmusclemass and strength, exercise capacity, and survival in the context of cachexia and bodywasting,many of themin patientswith cancer. The aim of this article is to summarise clinical trials published over the last two years. Therapeutic approaches discussed here include appetite stimulants like megestrol acetate, L-carnitine, or melatonin, anti-inflammatory drugs like thalidomide, pentoxyphylline, or a monoclonal antibody against interleukin-1α as well as ghrelin and the ghrelin agonist anamorelin, nutritional support, and anabolics like enobosarm and testosterone.

AB - Bodywasting in the context of chronic illness is associatedwith reduced quality of life and impaired survival. Recent clinical trials have investigated different approaches to improve patients' skeletalmusclemass and strength, exercise capacity, and survival in the context of cachexia and bodywasting,many of themin patientswith cancer. The aim of this article is to summarise clinical trials published over the last two years. Therapeutic approaches discussed here include appetite stimulants like megestrol acetate, L-carnitine, or melatonin, anti-inflammatory drugs like thalidomide, pentoxyphylline, or a monoclonal antibody against interleukin-1α as well as ghrelin and the ghrelin agonist anamorelin, nutritional support, and anabolics like enobosarm and testosterone.

KW - Cachexia

KW - Cancer

KW - Therapy

KW - Wasting

UR - http://www.scopus.com/inward/record.url?scp=84933523187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84933523187&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2014.10.026

DO - 10.1016/j.ijcard.2014.10.026

M3 - Article

C2 - 25804188

AN - SCOPUS:84933523187

SN - 0167-5273

VL - 184

SP - 726

EP - 742

JO - International Journal of Cardiology

JF - International Journal of Cardiology

IS - 1

ER -

Treatment of cachexia: An overview of recent developments

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this